Cargando…

Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy

OBJECTIVE: Several recent studies have identified a potential interaction between the vaginal microbiota and gynecological cancers, but little is known about the cervical microbiota and its changes during cancer treatment. Therefore, the aim of the study was to evaluate the quantitative and qualitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsakmaklis, Anastasia, Vehreschild, Maria, Farowski, Fedja, Trommer, Maike, Kohler, Christhardt, Herter, Jan, Marnitz, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497561/
https://www.ncbi.nlm.nih.gov/pubmed/32376743
http://dx.doi.org/10.1136/ijgc-2019-000801
_version_ 1783583343731802112
author Tsakmaklis, Anastasia
Vehreschild, Maria
Farowski, Fedja
Trommer, Maike
Kohler, Christhardt
Herter, Jan
Marnitz, Simone
author_facet Tsakmaklis, Anastasia
Vehreschild, Maria
Farowski, Fedja
Trommer, Maike
Kohler, Christhardt
Herter, Jan
Marnitz, Simone
author_sort Tsakmaklis, Anastasia
collection PubMed
description OBJECTIVE: Several recent studies have identified a potential interaction between the vaginal microbiota and gynecological cancers, but little is known about the cervical microbiota and its changes during cancer treatment. Therefore, the aim of the study was to evaluate the quantitative and qualitative changes of cervical microbiota in patients undergoing concurrent chemotherapy and radiation treatment for locally advanced cervical cancer. METHODS: Cervical cytobrush samples of 15 cervical patients undergoing chemoradiation treatment were collected 1 day before starting external beam radiation therapy and on the day of the last fraction of brachytherapy. After DNA extraction, 16S rRNA amplicon sequencing of the V3–V4 region was performed on the MiSeq platform, followed by data processing and statistical analyses concerning the alpha and beta diversity of 16 samples (7 samples were excluded because of incomplete sample sets). RESULTS: The amount of amplicon yield after polymerase chain reaction analysis in post-radiation samples was significantly lower compared with the baseline samples (pre 31.49±24.07 ng/µl; post 1.33±1.94 ng/µl; p=0.007). A comparison of pre-treatment and post-treatment samples did not show significant differences regarding beta diversity (weighted UniFrac). There was no significant difference in alpha diversity, which is used to characterize species diversity within a particular community and takes into account both number and abundance (Shannon Diversity Index pre-treatment samples: 2.167±0.7504 (95% CI 1.54 to 2.79); post-treatment samples: 1.97±0.43 (95% CI 1.61 to 2.33); p=0.38). Interindividual differences in patients could partly explain some variation of the samples (permutational multivariate analysis of variance). CONCLUSION: There was a strong reduction in cervical bacterial loads after chemoradiation. Neither alpha nor beta diversity varied significantly when baseline samples were compared with post-treatment samples.
format Online
Article
Text
id pubmed-7497561
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74975612020-09-28 Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy Tsakmaklis, Anastasia Vehreschild, Maria Farowski, Fedja Trommer, Maike Kohler, Christhardt Herter, Jan Marnitz, Simone Int J Gynecol Cancer Original Research OBJECTIVE: Several recent studies have identified a potential interaction between the vaginal microbiota and gynecological cancers, but little is known about the cervical microbiota and its changes during cancer treatment. Therefore, the aim of the study was to evaluate the quantitative and qualitative changes of cervical microbiota in patients undergoing concurrent chemotherapy and radiation treatment for locally advanced cervical cancer. METHODS: Cervical cytobrush samples of 15 cervical patients undergoing chemoradiation treatment were collected 1 day before starting external beam radiation therapy and on the day of the last fraction of brachytherapy. After DNA extraction, 16S rRNA amplicon sequencing of the V3–V4 region was performed on the MiSeq platform, followed by data processing and statistical analyses concerning the alpha and beta diversity of 16 samples (7 samples were excluded because of incomplete sample sets). RESULTS: The amount of amplicon yield after polymerase chain reaction analysis in post-radiation samples was significantly lower compared with the baseline samples (pre 31.49±24.07 ng/µl; post 1.33±1.94 ng/µl; p=0.007). A comparison of pre-treatment and post-treatment samples did not show significant differences regarding beta diversity (weighted UniFrac). There was no significant difference in alpha diversity, which is used to characterize species diversity within a particular community and takes into account both number and abundance (Shannon Diversity Index pre-treatment samples: 2.167±0.7504 (95% CI 1.54 to 2.79); post-treatment samples: 1.97±0.43 (95% CI 1.61 to 2.33); p=0.38). Interindividual differences in patients could partly explain some variation of the samples (permutational multivariate analysis of variance). CONCLUSION: There was a strong reduction in cervical bacterial loads after chemoradiation. Neither alpha nor beta diversity varied significantly when baseline samples were compared with post-treatment samples. BMJ Publishing Group 2020-09 2020-05-05 /pmc/articles/PMC7497561/ /pubmed/32376743 http://dx.doi.org/10.1136/ijgc-2019-000801 Text en © IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Tsakmaklis, Anastasia
Vehreschild, Maria
Farowski, Fedja
Trommer, Maike
Kohler, Christhardt
Herter, Jan
Marnitz, Simone
Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title_full Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title_fullStr Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title_full_unstemmed Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title_short Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
title_sort changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497561/
https://www.ncbi.nlm.nih.gov/pubmed/32376743
http://dx.doi.org/10.1136/ijgc-2019-000801
work_keys_str_mv AT tsakmaklisanastasia changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT vehreschildmaria changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT farowskifedja changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT trommermaike changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT kohlerchristhardt changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT herterjan changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy
AT marnitzsimone changesinthecervicalmicrobiotaofcervicalcancerpatientsafterprimaryradiochemotherapy